Stock ASTRAZEN ASTRAZENECA PHARMA INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company AstraZeneca Pharma India Limited

Equities

ASTRAZEN

INE203A01020

Pharmaceuticals

Delayed Bombay S.E.
Other stock markets
 02:10:02 2024-04-23 am EDT 		5-day change 1st Jan Change
5,246 INR +0.53% Intraday chart for AstraZeneca Pharma India Limited -0.81% -4.97%
Apr. 08 AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director CI
Mar. 25 AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024 CI

Business Summary

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

Sales per Business

INR in Million2022Weight2023Weight Delta
Tablets
75.2 %
6,491 80.6 % 7,543 75.2 % +16.21%
Injectables
16.7 %
937 11.6 % 1,674 16.7 % +78.56%
Clinical Trials
6.1 %
442 5.5 % 612 6.1 % +38.57%
Inhalation
2.0 %
186 2.3 % 201 2.0 % +8.06%

Sales per region

INR in Million2022Weight2023Weight Delta
India
93.6 %
7,592 94.2 % 9,389 93.6 % +23.68%
International
6.4 %
464 5.8 % 641 6.4 % +37.95%

Managers

Managers TitleAgeSince
Siva Padmanabhan CEO
 Chief Executive Officer - -
Sanjeev Panchal CEO
 Chief Executive Officer - 03-01-31
Bhavana Agrawal DFI
 Director of Finance/CFO - 23-09-30
Anil Kukreja CTO
 Chief Tech/Sci/R&D Officer - -
Manasa Rama CMP
 Compliance Officer - 22-08-10
Hooi-Bien Chuah BRD
 Director/Board Member - 21-03-31
Pankaj Jain LAW
 General Counsel - -
Rishi Kapur LAW
 General Counsel - -
Amarpreet Kaur Ahuja HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Revathy Ashok BRD
 Director/Board Member 65 16-12-01
Narayan Keelveedhi Seshadri CHM
 Chairman 67 12-12-05
Shilpa Nirula Divekar BRD
 Director/Board Member 50 21-12-28
Ankush Nandra BRD
 Director/Board Member 52 20-05-17
Sanjeev Panchal CEO
 Chief Executive Officer - 03-01-31
Bhavana Agrawal DFI
 Director of Finance/CFO - 23-09-30
Hooi-Bien Chuah BRD
 Director/Board Member - 21-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,000,000 4,393,759 ( 17.58 %) 0 17.58 %

Shareholders

NameEquities%Valuation
ASTRAZENECA PLC
75.00 %
18,750,000 75.00 % 1 196 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt)
2.881 %
720,282 2.881 % 46 M ₹
Tejas B Trivedi
2.716 %
679,078 2.716 % 43 M ₹
Shivani Tejas Trivedi
2.389 %
597,240 2.389 % 38 M ₹
Minaxi Bhalchandra Trivedi
1.843 %
460,720 1.843 % 29 M ₹
Prashant Jain
1.012 %
253,000 1.012 % 16 M ₹
Government of India
0.4317 %
107,932 0.4317 % 7 M ₹
quant Money Managers Ltd.
0.0465 %
11,622 0.0465 % 741 389 ₹
Motilal Oswal Asset Management Co. Ltd.
0.0118 %
2,939 0.0118 % 187 484 ₹
SBI Funds Management Ltd.
0.0104 %
2,598 0.0104 % 165 731 ₹

Company contact information

AstraZeneca Pharma India Ltd.

Manyata Embassy Business Park Outer Ring Road, Rachenahalli

560045, Bangalore

+91 80 6774 8000

http://www.astrazeneca.in
address AstraZeneca Pharma India Limited(ASTRAZEN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
ASTRAZENECA PHARMA INDIA LIMITED Stock AstraZeneca Pharma India Limited
-4.97% 1.56B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.46% 659B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.38% 557B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.86% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.44% 322B
ABBVIE INC. Stock AbbVie Inc.
+8.34% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.13% 215B
NOVARTIS AG Stock Novartis AG
+2.93% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-7.65% 200B
PFIZER, INC. Stock Pfizer, Inc.
-8.79% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ASTRAZEN Stock
  4. Company AstraZeneca Pharma India Limited